Ground News

See every side of every news story

rarecancernews.com image

News from rarecancernews.com

See all of rarecancernews.com news coverage in one place. Discover how rarecancernews.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve aggregated 59 of rarecancernews.com’s headlines and news stories over the past 3 months.

rarecancernews.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is rarecancernews.com credible or reliable? Our Factuality score answers both of those questions. When it comes to rarecancernews.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about rarecancernews.com

Where is rarecancernews.com located?rarecancernews.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top rarecancernews.com News

Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer

Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer

Over the past four decades, there has been increasing concern that perineal use of talc powder, a commonly used personal care product, might be associ…See the Story

Breakthrough: New Multiple Myeloma Drug Achieves 95% Survival Rate in 4-Year Clinical Trial

Breakthrough: New Multiple Myeloma Drug Achieves 95% Survival Rate in 4-Year Clinical Trial

Phase 3 trial reveals unprecedented 95% progression-free survival in multiple myeloma patients. See complete efficacy data and sustained response rates. Get insights.See the Story

Glioblastoma treatment lucicebtide well tolerated in clinical trial

Mississippi · Mississippi

Glioblastoma treatment lucicebtide well tolerated in clinical trial

Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of glioma, a form of brain cancer. Trial data also indicate that the therapy is working as expected and that it may help delay cancer progression. That’s according to data that Sapience Therapeutics, the therapy’s developer, shared at the American Society of Clinical Oncology’s annual meeting, held…Read Article

EBC-129 Receives FDA Fast-Track Designation for PDAC

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.United States · United States See the Story

FDA Accepts, Grants Priority Review to Sibeprenlimab BLA for IgA Nephropathy

With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.United States · United States See the Story

First patient dosed in Phase 1 trial testing AML T-cell treatment

The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid leukemia (AML), a form of blood cancer — has been dosed, according to the company. “The completion of first-in-human dosing represents a clinical development milestone for CER-1236,” Robert Sikorski, MD, PhD, chief medical officer of Cero, said in a company press release. About 18 adults wi…Maryland · Maryland Read Article

1st patient dosed in trial of PRMT5 inhibitor for glioblastoma

The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP deletion, including glioblastoma. The trial (NCT06810544) is evaluating the safety, pharmacological properties, and antitumor activity of Tango Therapeutics‘ TNG456 given alone or in combination with abemaciclib, a medication used in the treatment of certain types of breast cancer. TNG456 is being…Maryland · Maryland Read Article

Immunotherapy IMNN-001 extends survival in ovarian cancer: Data

When added to standard care, Imunon’s immunotherapy candidate IMNN-001 extended the average survival for people with newly diagnosed advanced ovarian cancer by more than a year, according to new clinical trial data. These results will be shared in an oral presentation next week at the annual meeting of the American Society of Clinical Oncology, and will also be simultaneously published in the journal Gynecologic Oncology, per an Imunon press rel…Mississippi · Mississippi Read Article

State Officials Unveil New Resource for Unpaid Caregivers

100% Center coverage: 1 sources

Pennsylvania state officials have unveiled a new support system for unpaid caregivers.NDP See the Story

The unspoken weight of becoming a caregiver

I’ll never forget the day that my mother was diagnosed with myeloma. That was when the word “son” was entirely erased from my identity. Without any warning whatsoever, I became everything to my mother: her advocate, nurse, and custodian of all the secrets she wasn’t confident (or trusting) enough to speak aloud. This column is for all of the weary and worn-out souls who have ever Googled the phrase “caregiver mental health” at 2 a.m. My name is …Mississippi · Mississippi Read Article

New AI blood test tracks pancreatic cancer treatment response

67% Center coverage: 3 sources

An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient's blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.Artificial Intelligence See the Story

Breaking News Topics Related to rarecancernews.com